EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Lineage Cell Therapeutics's Enterprise Value is $261.95 Mil.
Lineage Cell Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $-22.59 Mil. Therefore, Lineage Cell Therapeutics's EV-to-FCF for today is -11.60.
The historical rank and industry rank for Lineage Cell Therapeutics's EV-to-FCF or its related term are showing as below:
LCTX'
s EV-to-FCF Range Over the Past 10 Years
Min: -20.84 Med: -6.14 Max: 314.27
Current: -11.6
During the past 13 years, the highest EV-to-FCF of Lineage Cell Therapeutics was 314.27. The lowest was -20.84. And the median was -6.14.
LCTX's EV-to-FCF is ranked worse than 100% of 330
companies
in the Biotechnology industry
Industry Median: 14.97
vs LCTX: -11.60
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Lineage Cell Therapeutics's PE Ratio (TTM) for today is calculated as:
Lineage Cell Therapeutics's share price for today is $1.26.
Lineage Cell Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.290.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Lineage Cell Therapeutics EV-to-FCF Related Terms
Lineage Cell Therapeutics EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Lineage Cell Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lineage Cell Therapeutics EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lineage Cell Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Lineage Cell Therapeutics's EV-to-FCF falls into.
Lineage Cell Therapeutics's current Enterprise Value is $261.95 Mil.
Lineage Cell Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-22.59 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lineage Cell Therapeutics (LCTX) has a EV-to-FCF of -11.60 as of Jun. 25, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Lineage Cell Therapeutics and its competitors. According to the industry distribution chart, Lineage Cell Therapeutics ranks #999999 out of 330 companies in the Biotechnology industry.
Is Lineage Cell Therapeutics' EV-to-FCF too high?
Lineage Cell Therapeutics' current EV-to-FCF is -11.60. Based on the distribution chart, Lineage Cell Therapeutics ranks #999999 out of 330 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Lineage Cell Therapeutics has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Lineage Cell Therapeutics' EV-to-FCF compare to FATE and ABEO?
According to the Biotechnology industry distribution chart, Lineage Cell Therapeutics ranks #999999 out of 330 companies for EV-to-FCF. This places Lineage Cell Therapeutics in the lower half of its industry. The industry median EV-to-FCF is 14.97. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.97, based on 330 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Lineage Cell Therapeutics and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lineage Cell Therapeutics's current EV-to-FCF is -11.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lineage Cell Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Lineage Cell Therapeutics (LCTX) is currently considered Fairly Valued. The stock's GF Value™ is $1.33, compared to a current price of $1.26 — trading 5.3% below its estimated fair value. The current EV-to-FCF is -11.60. Lineage Cell Therapeutics' overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Lineage Cell Therapeutics (LCTX), the current EV-to-FCF is -11.60 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lineage Cell Therapeutics (LCTX) Overvalued in 2026?
Based on GuruFocus' analysis, Lineage Cell Therapeutics stock appears to be undervalued.
The current stock price of $1.26 is trading 5.3% below its estimated GF Value™ of $1.33.
GuruFocus considers Lineage Cell Therapeutics to be Fairly Valued.
Key valuation signals for LCTX:
EV-to-FCF: -11.60
GF Value™: $1.33 vs. price of $1.26 (5.3% below fair value)
No single metric tells the full story. See the LCTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.
78GF Score
Get the complete analysis for LCTX
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LCTX has been successfully added to your 
